Cash flow remains negative with a $1.1 million outflow in 2025Q3 and an OCF/NI ratio of 0.38, highlighting the firm's inability to self-fund its research activities.
| Cash from Operations | -5.55M | -2.95M | -446.92K | -599.57K | -284.02K |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -7708.17% | -559.3% | 25.46% | -111.1% | - |
| Net Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 495.5K | 2.65M | 0 | 1.4K | 821.15K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.83M | 403.71K | 0 | 0 | 0 |
| Working Capital Changes | -587.04K | 150.57K | 260.54K | -2.38K | 3.85K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.86K | -187.57K | 104K | -7.12K | -12.9K |
| Cash from Investing | 0 | -123.5K | 23.85K | -125.41K | 0 |
| Capital Expenditures | 0 | -123.5K | -13.89K | -125.41K | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 37.74K | 0 | 0 |
| Cash from Financing | 12.85M | 3.13M | 350K | 500K | 250K |
| Debt Issued (Net) | 591.29K | 2.18M | 159K | -8.51K | 0 |
| Equity Issued (Net) | 1.13M | 175K | 100K | 750K | 250K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -120K | 0 | 0 | 0 |
| Other Financing | -259.13K | 778.94K | 91K | -241.49K | 0 |
| Net Change in Cash | 7.3M | 60.93K | -73.06K | -224.98K | -34.02K |
| Free Cash Flow | -5.55M | -3.07M | -460.8K | -724.98K | -284.02K |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | -201.42% | -566.23% | 36.44% | -155.26% | - |
| FCF per Share | -0.09 | -0.16 | -0.00 | -0.00 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.48x | 0.63x | 1.00x | 0.26x |
| Interest Paid | 0 | 2.46K | 78.5K | 19.62K | 0 |
| Taxes Paid | 0 | 551.59K | 0 | 0 | 0 |
Imminent liquidity insolvency risk
As reported in recent financial statements, KLTO's operating cash flow of -$1.1 million in 2025Q3 against a net loss of $2.9 million highlights a persistent disconnect, with the OCF/NI ratio of 0.38 suggesting that accounting losses are not fully capturing the underlying cash-based operational requirements.
The divergence between net income and operating cash flow is typical for pre-revenue biotech, yet the consistent negative cash flow indicates that the company is consuming resources faster than it can generate value. Investors should monitor whether this gap narrows as the company attempts to transition toward clinical milestones, though current figures suggest a heavy reliance on external funding to bridge the operational deficit.
Based on KLTO's reported figures, the company has maintained a consistent negative free cash flow trajectory, with the 2025Q2 outflow reaching $2.0 million, underscoring the firm's inability to self-fund its research and development activities without continuous access to capital markets.
The lack of positive free cash flow is a structural reality for a pre-revenue entity, but the magnitude of the burn relative to the company's limited cash reserves warrants extreme caution. This trajectory suggests that the company remains entirely dependent on dilutive financing events to sustain its ongoing preclinical programs.
According to recent SEC filings, KLTO's working capital movements have been highly erratic, shifting from a $464.9K outflow in 2025Q1 to a $26.6K inflow in 2025Q3, which reflects the company's struggle to manage payables and operational liabilities amidst a severely constrained liquidity environment.
These fluctuations in working capital appear to be a byproduct of the company's efforts to manage its limited cash position by timing payments to vendors and service providers. Such volatility may indicate that the firm is prioritizing survival over operational efficiency, potentially creating future bottlenecks in its clinical development timeline.
As highlighted in financial disclosures, the company's cash flow statement obscures the impact of stock-based compensation, which reached $495.5K in 2025Q1, effectively serving as a non-cash expense that masks the true economic cost of talent retention in a cash-starved environment.
While stock-based compensation preserves immediate cash, it represents a significant future dilution risk for shareholders that is not fully captured in the headline cash burn metrics. Analysts should interpret these non-cash adjustments as a necessary, albeit costly, mechanism for the company to maintain its R&D operations without depleting its remaining cash reserves.
Quick answers to the most common questions about buying KLTO stock.
Klotho Neurosciences, Inc. (KLTO) generated $-2.9M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Klotho Neurosciences, Inc. (KLTO) reported negative free cash flow of $3.1M in 2024, indicating capital requirements exceeded cash from operations.
Klotho Neurosciences, Inc. (KLTO) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, Klotho Neurosciences, Inc. (KLTO) spent $0.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.